This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Antibiotic Resistance 2013: The Antibiotics Development Pipeline And Strategies To Combat Antibiotic Resistance

Table 4.5 Antibiotics in preclinical development (Source: Biopharm Reports, 2013)

Figures

Figure 2.1 Escherichia coli: trends of resistance to aminopenicillin by country, 2007–2010

Figure 2.2 Escherichia coli: trends of resistance to third-generation cephalosporins by country, 2007–2010

Figure 2.3 Escherichia coli: trends of resistance to fluoroquinolones by country, 2007–2010

Figure 2.4 Escherichia coli: trends of resistance to aminoglycosides by country, 2007–2010

Figure 2.5 Escherichia coli: trends of combined resistance (resistant to fluoroquinolones,

third-generation cephalosporins and aminoglycosides) by country, 2007–2010

Figure 2.6 Streptococcus pneumoniae: trends of non-susceptibility to penicillin by country, 2007–2010

Figure 2.7 Streptococcus pneumoniae: trends of non-susceptibility to macrolides by country, 2007–2010

Figure 2.8 Staphylococcus aureus: trends of resistance to meticillin (MRSA) by country, 2007–2010

Figure 2.9 Enterococcus faecalis: trends of high-level resistance to aminoglycosides by country, 2007–2010

Figure 2.10 Enterococcus faecium: trends of resistance to vancomycin by country 2007–2010

Figure 2.11 Klebsiella pneumoniae: trends of resistance to third-generation cephalosporins by country, 2007–2010

Figure 2.12 Klebsiella pneumoniae: trends of resistance to fluoroquinolones by country, 2007–2010

Figure 2.13 Klebsiella pneumoniae: trends of resistance to aminoglycosides by country, 2007–2010

Figure 2.14 Klebsiella pneumoniae: trends of resistance to carbapenems by country, 2007–2010

Figure 2.15 Klebsiella pneumoniae: trends of combined resistance (third-generation cephalosporins, fluoroquinolones and aminoglycosides) by country, 2007–2010

Figure 2.16 Pseudomonas aeruginosa: trends of resistance to piperacillin±tazobactam by country, 2007–2010

Figure 2.17 Pseudomonas aeruginosa: trends of resistance to ceftazidime by country, 2007–2010

Figure 2.18 Pseudomonas aeruginosa: trends of resistance to fluoroquinolones by country, 2007–2010

Figure 2.19 Pseudomonas aeruginosa: trends of resistance to aminoglycosides by country, 2007–2010

Figure 2.20 Pseudomonas aeruginosa: trends of resistance to carbapenems by country, 2007–2010

Figure 2.21 Pseudomonas aeruginosa: trends of combined resistance (R to three or more antibiotic classes among piperacillin±tazobactam, ceftazidime, fluoroquinolones, aminoglycosides and carbapenems) by country, 2007–2010

Figure 2.22 Antibiotic resistance of Staphylococcus, Streptococcus, Escherichia coli and Enterococcus in the US, Egypt and Tunisia 2.1

Figure 3.1 Current fully approved/marketed antibiotics for the treatment of bacterial and fungal infections (Source: Biopharm Reports, 2013).

6 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs